Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Transocean Ltd (RIG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Transocean Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $300.02 (market cap $39.89B), while Transocean Ltd trades at $5.27 (market cap $5.76B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 6.9× Transocean Ltd's market cap, and Transocean Ltd is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | RIG | |
|---|---|---|
Market Cap | $39.89B | $5.76B |
Sector | Health | Technology |
52-Week High | $491.22 | $7.58 |
52-Week Low | $278.09 | $2.55 |
Enterprise Value | $38.15B | $10.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Transocean Ltd. (RIG) trades at $5.20, up 1.17% today, with a bearish technical signal and mixed earnings history. The company reported a net loss of -$2.92 billion for 2025 but maintains strong revenue of $3.97 billion and a gross margin of 84.88%. Recent news highlights a $1 billion contract with Equinor and a pending merger with Valaris, aimed at reducing leverage and unlocking synergies.
The outlook is cautiously optimistic, with analyst consensus pointing to a $7.00 price target and 39% buy ratings. Key opportunities include backlog growth and merger benefits, while risks involve persistent net losses, oil price volatility, and execution challenges. The stock's valuation appears attractive with a P/B of 0.7, but profitability remains a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
